Gilead receives hepatitis C patent dispute with Merck to right costs from that
A US-Amtsrichter decided that of Gilead Sciences Inc. requirement on the refund of the right costs has, which developed for it from the Hepatits C law case with the pharmaceutical company Merck & Co Inc.
In June Gilead was released from a payment of damages payment at a value of $ 200 million for the injury of two patents from Merck, which stood in connection with blockbuster drugs Sovaldi and Harvoni of Gilead, after a US-judge uncovered a sample of failure on the part of Merck, including the perjury and other unethical actions.
In the case of collection of the complaint on Thursday US-Amtsrichterin Beth Labson Freeman said that Gilead has requirement on decree of the costs, which developed during the defense of the case.
Merck tries to draw even with Gilead, which controls the market of a new generation of hepatitis C medicines, which can heal over 90 percent of the patients with the liver disease.
The case decreases to the year 2013, when Gilead and Merck sued themselves mutually and took property up for laboratory work, which Sofosbuvir was the basis, the active ingredient in the medicines of Gilead.
